Targeting lipid mediators in cancer biology
暂无分享,去创建一个
[1] B. Schmidt,et al. Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma , 2018, Neuropharmacology.
[2] Charles N Serhan,et al. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. , 2018, Journal of Clinical Investigation.
[3] R. DuBois,et al. Role of prostanoids in gastrointestinal cancer. , 2018, The Journal of clinical investigation.
[4] Y. Surh,et al. RvD1 inhibits TNFα-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. , 2018, Biochemical and biophysical research communications.
[5] Sui Huang,et al. Resolvins suppress tumor growth and enhance cancer therapy , 2018, The Journal of experimental medicine.
[6] R. Collins,et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.
[7] Wenjun Wang,et al. Potential plasma lipid biomarkers in early-stage breast cancer , 2017, Biotechnology Letters.
[8] R. Melillo,et al. Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways , 2017, Oncoimmunology.
[9] A. Wright,et al. Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products , 2017, Anti-cancer drugs.
[10] I. Roitt,et al. Lipoxin A4 selectively programs the profile of M2 tumor‐associated macrophages which favour control of tumor progression , 2017, International journal of cancer.
[11] C. Serhan,et al. Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages , 2016, Proceedings of the National Academy of Sciences.
[12] Wen-hui Li,et al. Aspirin-triggered resolvin D1 inhibits TGF-β1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress. , 2016, International journal of molecular medicine.
[13] N. Sharma-Walia,et al. Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis , 2016, Journal of Virology.
[14] Y. Kanai,et al. Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma , 2016, Scientific Reports.
[15] Youping Deng,et al. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions , 2016, Oncotarget.
[16] B. Zhu,et al. Lipidome in colorectal cancer , 2016, Oncotarget.
[17] R. DuBois,et al. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. , 2015, Gastroenterology.
[18] Bhupinder Bhullar,et al. Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human , 2015, Oncotarget.
[19] Katherine M Flegal,et al. Prevalence of Obesity Among Adults and Youth: United States, 2011-2014. , 2015, NCHS data brief.
[20] Shanshan Liu,et al. Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production , 2015, Scientific Reports.
[21] Z. Wang,et al. Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. , 2015, Cancer Letters.
[22] R. Glynn,et al. Prospective study of body size throughout the life‐course and the incidence of endometrial cancer among premenopausal and postmenopausal women , 2015, International journal of cancer.
[23] M. Kömhoff,et al. Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro , 2015, Mediators of inflammation.
[24] K. Larsson,et al. COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset , 2015, Proceedings of the National Academy of Sciences.
[25] M. Fiala,et al. Curcuminoids and ω-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon γ production , 2015, Front. Physiol..
[26] N. Boyd,et al. Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. , 2015, Journal of the National Cancer Institute.
[27] X. Terra,et al. Prostacyclin‐synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy , 2015, The Journal of pathology.
[28] Philip Levy Ho,et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.
[29] Yinghua Xu,et al. Body mass index and risk of renal cell cancer: A dose‐response meta‐analysis of published cohort studies , 2014, International journal of cancer.
[30] Nada B. Memon,et al. Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion. , 2014, International journal of cardiology.
[31] Honghe Zhang,et al. Association between dietary antioxidant vitamins intake/blood level and risk of gastric cancer , 2014, International journal of cancer.
[32] Charles N. Serhan,et al. Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.
[33] T. Tsujiuchi,et al. Diverse effects of LPA receptors on cell motile activities of cancer cells , 2014, Journal of receptor and signal transduction research.
[34] R. Lamuela-Raventós,et al. Dietary intake of vitamin K is inversely associated with mortality risk. , 2014, Journal of NutriLife.
[35] P. Couvreur,et al. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. , 2014, Chemical communications.
[36] I. Thompson,et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. , 2014, Journal of the National Cancer Institute.
[37] K. Goralski,et al. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells , 2014, Anti-cancer drugs.
[38] P. Faust,et al. Cholesterol biosynthesis and ER stress in peroxisome deficiency. , 2014, Biochimie.
[39] Hyundoo Hwang,et al. RhoA and Rac1 play independent roles in lysophosphatidic acid-induced ovarian cancer chemotaxis. , 2014, Integrative biology : quantitative biosciences from nano to macro.
[40] P. Couvreur,et al. Therapeutic Modalities of Squalenoyl Nanocomposites in Colon Cancer: An Ongoing Search for Improved Efficacy , 2014, ACS nano.
[41] D. Giugliano,et al. Metabolic syndrome and endometrial cancer: a meta-analysis , 2014, Endocrine.
[42] E. Larsson,et al. Antioxidants Accelerate Lung Cancer Progression in Mice , 2014, Science Translational Medicine.
[43] J. Liao,et al. C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia , 2013, PloS one.
[44] M. Park,et al. Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. , 2013, The international journal of biochemistry & cell biology.
[45] A. Ananthaneni,et al. Evaluation and correlation of serum lipid profile in oral and gastrointestinal cancer patients. , 2013, Journal of international oral health : JIOH.
[46] M. Underwood,et al. Thromboxane A2 receptor α promotes tumor growth through an autoregulatory feedback pathway. , 2013, Journal of molecular cell biology.
[47] Jeff S. Jasper,et al. 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology , 2013, Science.
[48] M. Peppelenbosch,et al. DMS triggers apoptosis associated with the inhibition of SPHK1/NF-κB activation and increase in intracellular Ca2+ concentration in human cancer cells , 2013, International journal of molecular medicine.
[49] L. T. Tan. Pharmaceutical agents from filamentous marine cyanobacteria. , 2013, Drug discovery today.
[50] Gabor Tigyi,et al. Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression , 2013, Cancer Immunology Research.
[51] C. Serhan,et al. Resolution phase lipid mediators of inflammation: agonists of resolution. , 2013, Current opinion in pharmacology.
[52] T. G. Grunewald,et al. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: A focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays , 2013, Biology of the cell.
[53] N. Geng,et al. Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis , 2013, Current medical research and opinion.
[54] Dale P Sandler,et al. Association between Urinary Prostaglandin E2 Metabolite and Breast Cancer Risk: A Prospective, Case–Cohort Study of Postmenopausal Women , 2013, Cancer Prevention Research.
[55] L. Degraffenried,et al. A Low Dietary Ratio of Omega-6 to Omega-3 Fatty Acids May Delay Progression of Prostate Cancer , 2013, Nutrition and cancer.
[56] Liangtao Zhang,et al. Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.
[57] S. Pyne,et al. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. , 2013, Cellular signalling.
[58] M. Barbacid,et al. Genetically engineered mouse models of pancreatic adenocarcinoma , 2013, Molecular oncology.
[59] C. Hudis,et al. Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer , 2013, Cancer Prevention Research.
[60] Xiaoman Liu,et al. IFN-γ-mediated downregulation of LXA4 is necessary for the maintenance of nonresolving inflammation and papilloma persistence. , 2013, Cancer research.
[61] Mikio Suzuki,et al. Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells , 2013, International journal of oncology.
[62] H. Tai,et al. Activation of Thromboxane A2 Receptor (TP) Increases the Expression of Monocyte Chemoattractant Protein -1 (MCP-1)/Chemokine (C-C motif) Ligand 2 (CCL2) and Recruits Macrophages to Promote Invasion of Lung Cancer Cells , 2013, PloS one.
[63] Yongzhi Yang,et al. Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies , 2013, PloS one.
[64] Dezhi Yang,et al. Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2 , 2013, Oncology letters.
[65] A. Colquhoun,et al. E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro , 2012, Lipids in Health and Disease.
[66] F. Tomasello,et al. PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation , 2012, Epigenetics.
[67] Belgin Dogan,et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota , 2012, Science.
[68] Y. Peterson,et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy , 2012, Nature chemical biology.
[69] Yasuhiro Yamamoto,et al. Cytotoxicity of 15-Deoxy-Δ12,14-prostaglandin J2 through PPARγ-independent Pathway and the Involvement of the JNK and Akt Pathway in Renal Cell Carcinoma , 2012, International journal of medical sciences.
[70] Jianjun Luo,et al. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. , 2012, European journal of cancer.
[71] R. Weinberg,et al. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. , 2012, Cancer discovery.
[72] M. Caleo,et al. New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase , 2012, Neuropharmacology.
[73] Claudio R. Santos,et al. Lipid metabolism in cancer , 2012, The FEBS journal.
[74] P. Couvreur,et al. Squalenoylation: a generic platform for nanoparticular drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[75] Venkatesh Kota,et al. Identification of C6‐ceramide‐interacting proteins in D6P2T Schwannoma cells , 2012, Proteomics.
[76] N. Shinohara,et al. Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner , 2012, Cancer science.
[77] C. Serhan,et al. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. , 2012, The American journal of pathology.
[78] Y. Daaka,et al. PGE2 Promotes Renal Carcinoma Cell Invasion through Activated RalA , 2012, Oncogene.
[79] Q. Zeng,et al. Association of Dyslipidemia with Renal Cell Carcinoma: A 1∶2 Matched Case-Control Study , 2012, PloS one.
[80] S. Narumiya,et al. Thromboxane A2 receptor signaling facilitates tumor colonization through P‐selectin‐mediated interaction of tumor cells with platelets and endothelial cells , 2012, Cancer science.
[81] Y. Hannun,et al. Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction , 2012, Molecular Cancer Therapeutics.
[82] Tara Karnezis,et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.
[83] Eugene Y. Kim,et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. , 2012, Cancer research.
[84] Y. Urade,et al. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma , 2011, Proceedings of the National Academy of Sciences.
[85] Sui Huang,et al. Regulation of inflammation in cancer by eicosanoids. , 2011, Prostaglandins & other lipid mediators.
[86] M. Maggiolini,et al. Glycerophospholipid synthesis as a novel drug target against cancer. , 2011, Current molecular pharmacology.
[87] K. Honn,et al. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis , 2011, Cancer and Metastasis Reviews.
[88] K. Honn,et al. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment , 2011, Cancer and Metastasis Reviews.
[89] J. Crowley,et al. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2011 .
[90] M. Cabot,et al. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer , 2011, Cancer biology & therapy.
[91] Y. Daaka,et al. Prostaglandin E2 Regulates Renal Cell Carcinoma Invasion through the EP4 Receptor-Rap GTPase Signal Transduction Pathway* , 2011, The Journal of Biological Chemistry.
[92] S. Pyne,et al. FTY720 Analogues as Sphingosine Kinase 1 Inhibitors , 2011, The Journal of Biological Chemistry.
[93] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[94] C. Serhan,et al. Novel anti-inflammatory--pro-resolving mediators and their receptors. , 2011, Current topics in medicinal chemistry.
[95] M. Underwood,et al. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor , 2011, Oncogene.
[96] E. Mallon,et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. , 2010, The American journal of pathology.
[97] Y. Miller,et al. Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression. , 2010, Lung cancer.
[98] D. Ye,et al. Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis , 2010, Molecular Cancer Therapeutics.
[99] R. DuBois,et al. Eicosanoids and cancer , 2010, Nature Reviews Cancer.
[100] A. Nohturfft,et al. Coordination of lipid metabolism in membrane biogenesis. , 2009, Annual review of cell and developmental biology.
[101] J. Klenk,et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria , 2009, British Journal of Cancer.
[102] G. Nicolini,et al. Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies , 2009, Neurobiology of Disease.
[103] C. Serhan,et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions , 2009, The Journal of experimental medicine.
[104] Takao Shimizu,et al. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.
[105] T. Karn,et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer , 2008, Breast Cancer Research and Treatment.
[106] J. Kwak,et al. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation , 2007, Apoptosis.
[107] J. Uddin,et al. Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.
[108] C. Serhan. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.
[109] Tianxin Yang,et al. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. , 2006, American journal of physiology. Renal physiology.
[110] P. Couvreur,et al. Squalenoyl nanomedicines as potential therapeutics. , 2006, Nano letters.
[111] M. Monden,et al. Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology , 2006, British Journal of Cancer.
[112] S. Solomon,et al. Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.
[113] J. Emberson,et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.
[114] Korey R. Johnson,et al. ©2005 FASEB The FASEB Journal express article 10.1096/fj.05-4331fje. Published online November 30, 2005. Sphingosine kinase 1 is up-regulated in colon carcinogenesis , 2022 .
[115] John Savill,et al. Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.
[116] S. Dudek,et al. Regulation of sphingosine 1‐phosphate‐induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and α‐actinin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[117] C. Serhan. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.
[118] R. DuBois,et al. PROSTAGLANDINS AND CANCER , 2005, Gut.
[119] A. Mantovani,et al. Cancer: Inflammation by remote control , 2005, Nature.
[120] S. Shoor,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.
[121] Jennifer Couzin,et al. Withdrawal of Vioxx Casts a Shadow Over COX-2 Inhibitors , 2004, Science.
[122] Yusuf A. Hannun,et al. Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.
[123] K. Maeyama,et al. The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. , 2004, Biochemical pharmacology.
[124] J. Abrams,et al. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. , 2003, Archives of biochemistry and biophysics.
[125] G. Anderson,et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.
[126] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[127] C. Serhan,et al. Resolvins , 2002, The Journal of Experimental Medicine.
[128] Xìao-chun Xu. COX-2 inhibitors in cancer treatment and prevention, a recent development. , 2002, Anti-cancer drugs.
[129] A. Verin,et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.
[130] H. Rüdiger,et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. , 2001, Cancer research.
[131] T. Willson,et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[132] E. Gelmann,et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. , 2000, Cancer research.
[133] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[134] V. Steele,et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. , 2000, Cancer research.
[135] B. Chung,et al. Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. , 1999, Clinical biochemistry.
[136] J. Morrow,et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.
[137] M. Peters-Golden,et al. Arachidonic Acid Is Preferentially Metabolized by Cyclooxygenase-2 to Prostacyclin and Prostaglandin E2 * , 1999, The Journal of Biological Chemistry.
[138] K. Savin,et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[139] T. MacDonald,et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study , 1997, BMJ.
[140] S. Narumiya,et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.
[141] L. Crofford,et al. COX-1 and COX-2 tissue expression: implications and predictions. , 1997, The Journal of rheumatology. Supplement.
[142] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[143] R. Kolesnick,et al. Kinase Suppressor of Ras Is Ceramide-Activated Protein Kinase , 1997, Cell.
[144] J. Pfeilschifter,et al. Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[145] J. Lehmann,et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.
[146] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[147] G. L. Le Breton,et al. Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. , 1993, The Journal of biological chemistry.
[148] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[149] J. Lindgren,et al. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. , 1991, Blood.
[150] C. Hamilton,et al. Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function , 1991, Journal of clinical pharmacology.
[151] S. Nakanishi,et al. Cloning and expression of cDNA for a human thromboxane A2 receptor , 1991, Nature.
[152] B. Samuelsson. From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriences , 1983 .
[153] W. Waddell,et al. Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.
[154] J. Oates,et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. , 1982, Journal of immunology.
[155] Robert A. Lewis,et al. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds , 1981, Nature.
[156] J. Robertson,et al. Synthesis of Prostaglandins and Thromboxane B2 by Cerebral Arteries , 1979, Stroke.
[157] A. Tashjian. Role of prostaglandins in the production of hypercalcemia by tumors. , 1978, Cancer research.
[158] T. Żebro,et al. PROSTAGLANDINS AND BREAST CANCER , 1977, The Lancet.
[159] T. Żebro,et al. Prostaglandins from tumours of human large bowel. , 1977, British Journal of Cancer.
[160] A. Tashjian,et al. Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells , 1975, Nature.
[161] A. Tashjian,et al. Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producing fibrosarcoma. , 1973, Prostaglandins.
[162] A. Tashjian,et al. Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. , 1972, Biochemical and biophysical research communications.
[163] S. Singer,et al. The Fluid Mosaic Model of the Structure of Cell Membranes , 1972, Science.
[164] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[165] D. Klein,et al. Prostaglandins: stimulation of bone resorption in tissue culture. , 1970, Endocrinology.
[166] E. Corey,et al. A new total synthesis of prostaglandins of the E1 and F1 series including 11-epiprostaglandins. , 1968, Journal of the American Chemical Society.
[167] E. Corey,et al. Total synthesis of prostaglandins. Synthesis of the pure dl-E1, -F(sub 1.alpha.), -F(sub 1.beta.), -A1, and -B1 hormones , 1968 .
[168] E. V. Van Scott,et al. The modulating influence of stromal environment on epithelial cells studied in human autotransplants. , 1961, The Journal of investigative dermatology.
[169] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[170] U. S. Euler. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). , 1936 .
[171] Cuthbert Dukes,et al. Origin of Cancer , 1938 .
[172] Haoyu Kuang,et al. Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-κB activity. , 2016, Oncology reports.
[173] Sung-Dae Cho,et al. Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. , 2013, Cancer letters.
[174] S. Saddoughi,et al. Diverse functions of ceramide in cancer cell death and proliferation. , 2013, Advances in cancer research.
[175] M. Kester,et al. Development and use of ceramide nanoliposomes in cancer. , 2012, Methods in enzymology.
[176] Kathryn A. Newman,et al. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. , 2011, Nutrition research.
[177] A. Hezel,et al. Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma , 2011 .
[178] J. Liou,et al. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta --> 14-3-3epsilon pathway. , 2009, Methods in molecular biology.
[179] S. Pettersson,et al. Cancer Inflammation , 2009, Mucosal Immunology.
[180] G. van Meer,et al. Cellular lipidomics , 2005, The EMBO journal.
[181] J. Couzin. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. , 2004, Science.
[182] B. Evers,et al. Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. , 2002, International journal of gastrointestinal cancer.
[183] B. Evers,et al. Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells , 2002 .
[184] H. Seyberth,et al. Localization of the prostacyclin receptor in human kidney. , 1998, Kidney international.
[185] Jasmine Chen,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[186] T. B. Osborne,et al. Nutrition classics from The Journal of Biological Chemistry 20:379-389, 1915. Further observations of the influence of natural fats upon growth. , 1973, Nutrition reviews.